Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Gains from Investment Securities (2016 - 2024)

Spyre Therapeutics' Gains from Investment Securities history spans 10 years, with the latest figure at -$200000.0 for Q2 2024.

  • For Q2 2024, Gains from Investment Securities fell 100.32% year-over-year to -$200000.0; the TTM value through Dec 2024 reached -$200000.0, up 84.91%, while the annual FY2023 figure was -$915000.0, 115.56% down from the prior year.
  • Gains from Investment Securities reached -$200000.0 in Q2 2024 per SYRE's latest filing, up from -$909000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $63.4 million in Q2 2023 to a low of -$909000.0 in Q3 2023.
  • Average Gains from Investment Securities over 5 years is $5.0 million, with a median of $429000.0 recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: tumbled 6733.33% in 2022, then skyrocketed 14682.61% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at -$15000.0 in 2020, then surged by 60.0% to -$6000.0 in 2021, then crashed by 6733.33% to -$410000.0 in 2022, then tumbled by 121.71% to -$909000.0 in 2023, then surged by 78.0% to -$200000.0 in 2024.
  • Per Business Quant, the three most recent readings for SYRE's Gains from Investment Securities are -$200000.0 (Q2 2024), -$909000.0 (Q3 2023), and $63.4 million (Q2 2023).